Keywords: ready-to-use, copaxone, launched, canada, teva, multiple, sclerosis
Ready-to-use Copaxone launched in Canada
Article | 27 May 2002
Teva's multiple sclerosis treatment Copaxone (glatiramer acetate) hasbeen launched in Canada in a new prefilled, ready-to-use syringe formulation.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
